Kenneth Anderson

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients

Patricia Pisciotto, K. Benson, Heather Hume et al. · Transfusion · 1995 · 127 citations

Demonstration of a keratan sulfate proteoglycan and a mannose-rich glycoconjugate in corpora amylacea of the brain by immunocytochemical and lectin-binding methods

H.Mei Liu, Kenneth Anderson, Bruce Caterson · Journal of Neuroimmunology · 1987 · 31 citations

Corpora Amylacea, Biochemistry, Bioanalysis +9

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution

Min Tang, Rui Zhao, Helgi van de Velde et al. · Clinical Cancer Research · 2016 · 28 citations · Full text

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Chia‐Jen Liu, Irene M. Ghobrial, Mark Bustoros et al. · Blood · 2018 · 24 citations